Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs – MedCity News
By Frank Vinluan Publication Date: 2026-08-23 17:34:00 Immunotherapy developer Abcuro received disappointing news this year as its lead drug candidate…
Tag: ABCuro
Abcuro secures $66m to support clinical trial of ulviprubart for IBM
By Salong Debbarma Publication Date: 2026-08-19 10:30:00 US-based biotechnology company Abcuro has closed a $66m Series D funding round to…
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise…
Abcuro Raises $200M to Fight IBM
Inclusion Body Myositis, or IBM, is a rare degenerative muscle disease…
Abcuro draws $200M to push muscle weakness drug over the finish line – FirstWord Pharma
Abcuro draws $200M to push muscle weakness drug over the finish line FirstWord Pharma Article Source https://firstwordpharma.com/story/5934611
ABCuro finishes enrolling participants for phase 2/3 IBM treatment trial – Pharmafile
Abcuro, a company specializing in musculoskeletal disorders, has recently completed enrollment for its MUSCLE registration phase 2/3 clinical trial. This…